• Homepage
  • Webinar - How to Evolve mRNA Production and Purification in the Aftermath of COVID-19 Vaccine Development

How to Evolve mRNA Production and Purification in the Aftermath of COVID-19 Vaccine Development

Although mRNA therapeutics have been around in the biopharmaceutical industry for several years, the success of mRNA-based COVID-19 vaccines has fully revealed the potential of this ground-breaking technology. Given the pressure of delivering during a pandemic, manufacturers have focused primarily on safety and efficacy of mRNA vaccines and not so much on how to optimize production and purification processes for future mRNA therapeutics.

Sartorius, however, was studying these issues even before the pandemic started. Our scientists have been developing mRNA processes in our labs in Ajdovščina, Slovenia, and they have amassed a wealth of information and insights about how next-generation processes can be developed and implemented. This webinar features an exclusive panel discussion where they will discuss current approaches and bottlenecks of mRNA production and lay out their vision for truly optimized next-generation processes.

Register and Watch Now

Key Learning Objectives

  • Review the real-world challenges our customers faced in their mRNA manufacturing efforts and how Sartorius partnered with them to develop innovative solutions

  • Underscore the importance of flexibility in mRNA purification and highlight some options from the Sartorius mRNA purification toolbox, such as the Oligo dT affinity monolith and PrimaS non-affinity monolith columns for the capture of mRNA

  • Present a method for rapid analytical monitoring of IVT reactions with CIMac® PrimaS

Meet Our Experts

Tomas Kostelec

Product Manager mRNA | pDNA

Tomas Kostelec has completed his Master’s in organic chemistry in Chemistry at University College London, with a focus on multimodal contrast agents for medical imaging. He joined BIA Separations, now part of Sartorius in 2016 as analytical scientist to support contract work and development activities for AAV, influenza, and other viruses. He is currently Product Manager for mRNA at Sartorius, his area of interest includes purification and analytics of mRNA.

Rok Sekirnik

Head of Process Development, mRNA/pDNA, Sartorius

Rok Sekirnik graduated with a degree in chemistry from the University of Oxford, where he also completed his PhD. His team at BIA Separations, now a Sartorius company, is focused on developing high-yielding, cost-effective purification approaches for pDNA and mRNA production.

Piergiuseppe Nestola

Manager of Process Technology Consultants, Sartorius

Piergiuseppe Nestola, PhD, is a Manager of Process Technology Consultants at Sartorius, where he is responsible for providing scientific, technological and process leadership in the field of viral-based therapeutics.

Amelie Boulais

Head of Market Entry Strategy, Viral -based Therapeutics , Sartorius

Amélie graduated from the Biotechnology Engineering Institute of Bordeaux, France (ENSTBB) and holds a degree in biotechnology engineering. Amelie in her current role is responsible for the go-to-market strategy covering both vaccine and gene therapy applications in the Viral-based Therapeutics segment at Sartorius.

Please Complete the Form

Complete Form to View the Webinar